Diagnostics - Global Diagnostics are the most important tools that empower the health workforce in the identification of diseases or health conditions They allow the initiation of treatments in order to avoid further complications and costly treatments for patients
Global Diagnostics Coalition The Global Diagnostics Coalition is a WHO managed network, administered and housed within WHO It has 3 objectives: Conduct advocacy activities that raise awareness and increase support of WHO diagnostic leadership and capacity strengthening efforts as essential health services for management of all health conditions Conduct advocacy activities to raise awareness of the essential role of
Strengthening diagnostics capacity - World Health Organization (WHO) In response, WHO established the Diagnostics Taskforce as a collaborative mechanism between all WHO programmes, at all three levels of the organization, to support the implementation of the resolution, and to serve as the entry point to all stakeholders working with countries on strengthening diagnostics capacity Taskforce members support
WHO issues its first-ever reports on tests and treatments for fungal . . . WHO's reports addressing the critical lack of medicines and diagnostic tools for invasive fungal diseases, shows urgent need for innovative research and development (R D) to close the gaps Fungal diseases are an increasing public health concern, with common infections growing increasingly resistant to treatment
WHO publishes new Essential Diagnostics List and urges countries to . . . To address the lack of access to tests and testing services in multiple countries, WHO since 2018 has published a yearly essential diagnostics list (EDL), a basket of recommended in vitro diagnostics that should be available at point-of-care and in laboratories in all countries to increase timely and life-saving diagnoses The latest edition, published today, includes WHO-recommended COVID-19
Landscape analysis of commercially available and pipeline in vitro . . . The Landscape analysis of commercially available and pipeline in vitro diagnostics for fungal priority pathogens focuses on commercially available diagnostic products and pipeline diagnostic products for invasive fungal diseases (IFDs) and on the identifiable gaps
Redefining the HIV response in Africa through local production of . . . To boost supply chain resilience and regional self-reliance, WHO has been actively advocating for locally manufactured quality-assured medicines and diagnostics In 2023, a Kenya-based pharmaceutical company became the first African manufacturer to receive WHO prequalification to produce tenofovir disoproxil fumarate, lamivudine and dolutegravir (TLD), a WHO-recommended first-line
In vitro diagnostics - Global - World Health Organization (WHO) In vitro diagnostics (IVDs) are tests that can detect disease, conditions and infections In vitro simply means ‘in glass’, meaning these tests are typically conducted in test tubes and similar equipment, as opposed to in vivo tests, which are conducted in the body itself
Is your doctor’s AI safe? - World Health Organization (WHO) AI tools are increasingly present in the Region’s health systems Thirty-two countries (64%) are already using AI-assisted diagnostics, especially in imaging and detection Half of the countries in the Region (50%) have introduced AI chatbots for patient engagement and support, while 26 (52%) have identified priority areas for AI in health
WHO prequalifies the first triple diagnostic test for HIV, hepatitis B . . . On 10 July 2025, the World Health Organization (WHO) prequalified the first bundled set of three in vitro rapid diagnostic tests (RDTs) capable of simultaneously detecting HIV, hepatitis B virus (HBV) and syphilis – three major infections that pose serious risks to maternal and child health The prequalification listing of the Determine™ Antenatal Care Panel is expected to facilitate